Kevin Tang Biography and Net Worth



Mr. Tang has served as Chairman since 2014. He serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Since the company’s inception in 2013, Mr. Tang has served as the Chairman and Chief Executive Officer of Odonate Therapeutics, Inc. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

What is Kevin C. Tang's net worth?

The estimated net worth of Kevin C. Tang is at least $0.00 as of December 18th, 2023. Mr. Tang owns 3,850,513 shares of Odonate Therapeutics stock worth more than $0 as of April 28th. This net worth estimate does not reflect any other investments that Mr. Tang may own. Learn More about Kevin C. Tang's net worth.

How do I contact Kevin C. Tang?

The corporate mailing address for Mr. Tang and other Odonate Therapeutics executives is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. Odonate Therapeutics can also be reached via phone at (858) 731-8180 and via email at [email protected]. Learn More on Kevin C. Tang's contact information.

Has Kevin C. Tang been buying or selling shares of Odonate Therapeutics?

Kevin C. Tang has not been actively trading shares of Odonate Therapeutics during the last quarter. Most recently, Kevin C. Tang sold 365,289 shares of the business's stock in a transaction on Friday, November 19th. The shares were sold at an average price of $1.92, for a transaction totalling $701,354.88. Learn More on Kevin C. Tang's trading history.

Who are Odonate Therapeutics' active insiders?

Odonate Therapeutics' insider roster includes Aaron Davis (Director), and Kevin Tang (CEO). Learn More on Odonate Therapeutics' active insiders.

Kevin C. Tang Insider Trading History at Odonate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/19/2021Sell365,289$1.92$701,354.88View SEC Filing Icon  
11/17/2021Sell1,287,577$2.29$2,948,551.33View SEC Filing Icon  
12/23/2020Buy275,784$15.16$4,180,885.44
9/29/2020Buy110,882$13.13$1,455,880.66View SEC Filing Icon  
8/28/2020Buy1,052,631$14.25$14,999,991.75View SEC Filing Icon  
6/26/2019Buy769,231$26.00$20,000,006.00View SEC Filing Icon  
6/18/2019Buy50,000$26.15$1,307,500.00View SEC Filing Icon  
6/7/2019Buy76,308$27.36$2,087,786.88View SEC Filing Icon  
6/5/2019Buy93,692$24.92$2,334,804.64View SEC Filing Icon  
3/8/2019Buy140,000$18.26$2,556,400.00View SEC Filing Icon  
12/31/2018Buy63,700$13.11$835,107.00View SEC Filing Icon  
12/26/2018Buy60,000$12.60$756,000.00View SEC Filing Icon  
12/18/2018Buy40,000$14.67$586,800.00View SEC Filing Icon  
12/12/2018Buy20,000$15.60$312,000.00View SEC Filing Icon  
12/7/2018Buy20,000$14.79$295,800.00View SEC Filing Icon  
11/26/2018Buy16,937$15.29$258,966.73View SEC Filing Icon  
11/1/2018Buy10,000$14.87$148,700.00View SEC Filing Icon  
10/29/2018Buy10,235$14.98$153,320.30View SEC Filing Icon  
10/25/2018Buy39,765$15.35$610,392.75View SEC Filing Icon  
9/28/2018Buy40,000$19.16$766,400.00View SEC Filing Icon  
9/26/2018Buy40,000$19.75$790,000.00View SEC Filing Icon  
9/20/2018Buy90,000$19.55$1,759,500.00View SEC Filing Icon  
8/20/2018Buy49,685$19.49$968,360.65View SEC Filing Icon  
8/15/2018Buy22,810$18.93$431,793.30View SEC Filing Icon  
3/1/2018Buy14,050$27.42$385,251.00View SEC Filing Icon  
2/27/2018Buy28,612$27.42$784,541.04View SEC Filing Icon  
2/22/2018Buy39,083$27.17$1,061,885.11View SEC Filing Icon  
2/16/2018Buy128,255$22.47$2,881,889.85View SEC Filing Icon  
12/7/2017Buy1,291,666$24.00$30,999,984.00View SEC Filing Icon  
See Full Table

Kevin C. Tang Buying and Selling Activity at Odonate Therapeutics

This chart shows Kevin C Tang's buying and selling at Odonate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Odonate Therapeutics Company Overview

Odonate Therapeutics logo
Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.27
Low: $1.03
High: $1.55

2 Week Range

Now: N/A

Volume

87,682 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A